Shots:

• The two P-III MISSION AD1 and MISSION AD2 studies involves assessing of Elenbecestat (50mg) vs PBO in 2-100 patients with mild cognitive impairment or mild AD with confirmed amyloid pathology in the brain for 24mos.
• The discontinuation is based on the Data Safety Monitoring Board (DSMB) recommendation due to its unfavorable risk-benefit ratio. Additionally- the P-II clinical study (Study 202) of Elenbecestat will also be discontinued
• Elenbecestat (PO) is an investigational BACE inhibitor act by reducing amyloid plaque formations in the brain- thus slowing AD progression in the brain. The companies will continue to evaluate BAN2401 (beta-amyloid cleaving enzyme) in P-III CLARITY study

Ref: PRNewswire | Image:Biogen